MDT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medtronic looks like a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock is trading near $83 and sits close to its recent resistance band, but the broader setup is constructive: momentum is improving, analyst sentiment is mixed but still leans positive overall, hedge funds are buying, and the business continues to show durable dividend and revenue characteristics. Since the investor is impatient and does not want to wait for a perfect entry, I would favor buying now rather than holding out for a lower price.
Technically, MDT is showing a positive short-term trend. The MACD histogram is positive and expanding, which supports upward momentum. RSI_6 at 68.7 is elevated but not extreme, suggesting the stock is strong without being clearly overbought. Moving averages are converging, which often signals a transition phase and potential trend continuation. Price at 83.21 is slightly above pivot 80.564 and near R1 82.539 / R2 83.759, so the stock is pressing the upper part of its near-term range. The stock pattern data suggests a favorable near-term bias, with a 70% chance of 1.24% next day, 2.12% next week, and 4.91% next month.
["Medtronic reported its highest annual revenue growth in a decade.", "Hedge funds are buying, with buying amount up 167.88% over the last quarter.", "BTIG upgraded the stock to Buy and sees a re-rating opportunity.", "Needham kept a Buy rating and said the company is in the early stages of a strong product cycle.", "The company has a long dividend growth history and currently yields 3.5%, which supports long-term appeal.", "Technical momentum is improving with a positive and expanding MACD histogram."]
["Several analysts lowered price targets recently, reflecting caution on margins and 2027 guidance.", "Goldman Sachs, UBS, Baird, Truist, Stifel, and BofA all reduced targets, showing tempered expectations.", "Congress trading shows 1 sale and 0 purchases in the last 90 days, which is mildly negative.", "RSI is elevated near the upper end of the neutral range, so upside may be somewhat extended in the short term.", "Options IV is elevated, which suggests the market expects meaningful price movement and may be pricing in uncertainty."]
The latest quarter shown in the data is Q4, and it was solid. Revenue beat consensus and organic growth was described as broadly ahead of expectations. Needham noted Q4 revenue and EPS beat consensus, while other analysts said margins were softer and FY27 EPS guidance was below some estimates. Overall, the latest quarter points to improving top-line growth, but margin expansion is still a key watch item.
Analyst sentiment is mixed but not bearish. Recent moves include multiple price-target cuts, mainly due to conservative FY27 expectations, softer margins, and inflation/utilization concerns. However, several firms still keep Buy or Outperform ratings, including BofA, Bernstein, BTIG, and Needham. The pros view is that Medtronic has a durable business, improving organic growth, and potential re-rating upside. The cons view is that EPS growth has lagged, margins remain under pressure, and some firms expect only modest upside from current levels.
